Our findings support CARMA3 as a potential prognostic biomarker and therapeutic target in HCC and highlight triptolide as a promising adjuvant candidate for enhancing the efficacy of current treatments, particularly in chemoresistant HCC subtypes. This evidence concerns the gene CARD10 and hepatocellular carcinoma.